These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 22283751)

  • 21. [Muscarinic M1 and/or M4 receptor agonists as potential novel treatments for psychoses].
    Spoelstra SK; Visser L; Knegtering H
    Tijdschr Psychiatr; 2023; 65(9):555-562. PubMed ID: 37947466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors.
    Jakubík J; Bacáková L; El-Fakahany EE; Tucek S
    Mol Pharmacol; 1997 Jul; 52(1):172-9. PubMed ID: 9224827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M
    Gould RW; Grannan MD; Gunter BW; Ball J; Bubser M; Bridges TM; Wess J; Wood MW; Brandon NJ; Duggan ME; Niswender CM; Lindsley CW; Conn PJ; Jones CK
    Neuropharmacology; 2018 Jan; 128():492-502. PubMed ID: 28729220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological characterization of LY593093, an M1 muscarinic acetylcholine receptor-selective partial orthosteric agonist.
    Watt ML; Schober DA; Hitchcock S; Liu B; Chesterfield AK; McKinzie D; Felder CC
    J Pharmacol Exp Ther; 2011 Aug; 338(2):622-32. PubMed ID: 21558436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The antipsychotic potential of muscarinic allosteric modulation.
    Bridges TM; LeBois EP; Hopkins CR; Wood MR; Jones CK; Conn PJ; Lindsley CW
    Drug News Perspect; 2010 May; 23(4):229-40. PubMed ID: 20520852
    [TBL] [Abstract][Full Text] [Related]  

  • 26. M
    Fu L; Luo Y; Niu L; Lin Y; Chen X; Zhang J; Tang W; Chen Y; Jiao Y
    Bioorg Med Chem; 2024 May; 105():117728. PubMed ID: 38640587
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.
    Jones CK; Byun N; Bubser M
    Neuropsychopharmacology; 2012 Jan; 37(1):16-42. PubMed ID: 21956443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current Advances in Allosteric Modulation of Muscarinic Receptors.
    Jakubik J; El-Fakahany EE
    Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32085536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential role of muscarinic receptors in schizophrenia.
    Bymaster FP; Shannon HE; Rasmussen K; DeLapp NW; Ward JS; Calligaro DO; Mitch CH; Whitesitt C; Ludvigsen TS; Sheardown M; Swedberg M; Rasmussen T; Olesen PH; Jeppesen L; Sauerberg P; Fink-Jensen A
    Life Sci; 1999; 64(6-7):527-34. PubMed ID: 10069519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Muscarinic acetylcholine receptors as CNS drug targets.
    Langmead CJ; Watson J; Reavill C
    Pharmacol Ther; 2008 Feb; 117(2):232-43. PubMed ID: 18082893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduction in muscarinic M1-mediated hypercholinergic state and beneficial cognitive effects of muscarinic agonists in schizophrenia.
    Pomara N
    Am J Psychiatry; 2009 Jan; 166(1):111; author reply 111-3. PubMed ID: 19122018
    [No Abstract]   [Full Text] [Related]  

  • 32. Role of the cholinergic muscarinic system in bipolar disorder and related mechanism of action of antipsychotic agents.
    Bymaster FP; Felder CC
    Mol Psychiatry; 2002; 7 Suppl 1():S57-63. PubMed ID: 11986996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The muscarinic system, cognition and schizophrenia.
    Carruthers SP; Gurvich CT; Rossell SL
    Neurosci Biobehav Rev; 2015 Aug; 55():393-402. PubMed ID: 26003527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Muscarinic receptors and novel strategies for the treatment of age-related brain disorders.
    Ehlert FJ; Roeske WR; Yamamura HI
    Life Sci; 1994; 55(25-26):2135-45. PubMed ID: 7997072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases.
    Felder CC; Goldsmith PJ; Jackson K; Sanger HE; Evans DA; Mogg AJ; Broad LM
    Neuropharmacology; 2018 Jul; 136(Pt C):449-458. PubMed ID: 29374561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The M₁/M₄ preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia.
    Barak S; Weiner I
    Int J Neuropsychopharmacol; 2011 Oct; 14(9):1233-46. PubMed ID: 21211109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting Muscarinic Acetylcholine Receptors for the Treatment of Psychiatric and Neurological Disorders.
    Moran SP; Maksymetz J; Conn PJ
    Trends Pharmacol Sci; 2019 Dec; 40(12):1006-1020. PubMed ID: 31711626
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery and Development of Muscarinic Acetylcholine M
    Takai K; Enomoto T
    Chem Pharm Bull (Tokyo); 2018; 66(1):37-44. PubMed ID: 29311510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of muscarinic acetylcholine receptors via their allosteric binding sites.
    Jakubík J; Bacáková L; Lisá V; el-Fakahany EE; Tucek S
    Proc Natl Acad Sci U S A; 1996 Aug; 93(16):8705-9. PubMed ID: 8710935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders.
    Digby GJ; Shirey JK; Conn PJ
    Mol Biosyst; 2010 Aug; 6(8):1345-54. PubMed ID: 20582339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.